Dp-ucMGP as a Biomarker in Sarcopenia.

Area of Science:

• Gerontology and Biomedical Science
• Biomarker Discovery
• Metabolic and Cardiovascular Research

Background:

• Sarcopenia, characterized by muscle loss, increases risks of falls, osteoporosis, and mortality, posing a significant healthcare challenge.
• Current diagnostic biomarkers for sarcopenia, which involve bone, fat, and muscle, are insufficient.
• Matrix Gla Protein (MGP), an adipokine influencing bone metabolism, has been linked to diminished muscle strength.

Purpose of the Study:

• To investigate the association between dephosphorylated-uncarboxylated MGP (dp-ucMGP) and sarcopenia in asymptomatic individuals.
• To evaluate dp-ucMGP as a potential biomarker for sarcopenia diagnosis and characterization.

Main Methods:

• Analysis of serum dp-ucMGP levels in 1022 asymptomatic subjects from the BioPersMed cohort using the InaKtif MGP Kit.
• Assessment of dual-energy X-ray absorptiometry (DXA) for body composition and physical performance tests.
• Statistical correlation analysis between dp-ucMGP levels and sarcopenia parameters.

Main Results:

• Dp-ucMGP plasma levels showed significant correlations with gait speed (ρ = −0.192), appendicular skeletal muscle mass (ρ = 0.102), and appendicular skeletal muscle mass index (ρ = 0.112).
• Individuals with sarcopenia exhibited lower dp-ucMGP levels (p < 0.001), while those with reduced physical performance had higher levels (p = 0.019).
• The lowest quartile of dp-ucMGP was associated with the highest risk of reduced muscle mass, and the highest quartile with the highest risk of reduced muscle strength.

Conclusions:

• Dp-ucMGP levels are significantly associated with key parameters of sarcopenia, including muscle mass and physical performance.
• The study suggests that dp-ucMGP holds potential as a valuable biomarker for identifying and characterizing sarcopenia.
• Further research into dp-ucMGP could lead to improved diagnostic tools for sarcopenia.